Zi-Ming Zhao, Ph.D.
Understands molecular mechanisms of tumorigenesis and drug resistance using cancer clinical genomic data.
ABOUT ZI-MING ZHAO, Ph.D.
I have been interested in understanding genetic origins and molecular evolution of life and human diseases, and finding cures for various human diseases particularly cancer and infectious diseases. My current focus is studying cancer clinical genomics from the perspectives of molecular evolution and population genetics. My goal is to understand the process of tumorigenesis, metastasis and drug resistance, and to identify markers for cancer diagnosis, prognosis, and therapeutics.
Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene. 2018
Zhao ZM, Campbell MC, Li N, Lee DSW, Zhang Z, Townsend JP, Detection of regional variation in selection intensity within protein-coding genes using DNA sequence polymorphism and divergence, Molecular Biology and Evolution. 2017
Zhao ZM, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL, Townsend JP. Early and multiple origins of metastatic lineages within primary tumors. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2140-5.
Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao ZM, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2016 Sep 29. pii: mdw436.